Asthma Biomarkers: Do They Bring Precision Medicine Closer to the Clinic?

다국어 초록 (Multilingual Abstract)

Measurement of biomarkers has been incorporated within clinical research of asthma to characterize the population and to associate the disease with environmental and therapeutic effects. Regrettably, at present, there are no specific biomarkers, none is validated or qualified, and endotype-driven choices overlap. Biomarkers have not yet reached clinical practice and are not included in current asthma guidelines. Last but not least, the choice of the outcome upholding the value of the biomarkers is extremely difficult, since it has to reflect the mechanistic intervention while being relevant to both the disease and the particular person. On the verge of a new age of asthma healthcare standard, we must embrace and adapt to the key drivers of change. Disease endotypes, biomarkers, and precision medicine represent an emerging model of patient care building on large-scale biologic databases, omics and diverse cellular assays, health information technology, and computational tools for analyzing sizable sets of data. A profound transformation of clinical and research pattern from population to individual risk and from investigator-imposed subjective disease clustering (hypothesis driven) to unbiased, data-driven models is facilitated by the endotype/biomarker-driven approach.

참고문헌 (Reference)

1 Tang H, "YKL-40 in asthmatic patients, and its correlations with exacerbation, eosinophils and immunoglobulin E" 35 : 757-760, 2010

2 Agache I, "Untangling asthma phenotypes and endotypes" 67 : 835-846, 2012

3 Bullens DM, "Type III IFN-lambda mRNA expression in sputum of adult and school-aged asthmatics" 38 : 1459-1467, 2008

4 Hsia BJ, "Trif-dependent induction of Th17 immunity by lung dendritic cells" 8 : 186-197, 2015

5 Baines KJ, "Transcriptional phenotypes of asthma defined by gene expression profiling of induced sputum samples" 127 : 153-160, 2011

6 Chun E, "Toll-like receptor expression on peripheral blood mononuclear cells in asthmatics; implications for asthma management" 30 : 459-464, 2010

7 Roponen M, "Toll-like receptor 7 function is reduced in adolescents with asthma" 35 : 64-71, 2010

8 Wong CK, "Thymic stromal lymphopoietin induces chemotactic and prosurvival effects in eosinophils: implications in allergic inflammation" 43 : 305-315, 2010

9 Ying S, "Thymic stromal lymphopoietin expression is increased in asthmatic airways and correlates with expression of Th2-attracting chemokines and disease severity" 174 : 8183-8190, 2005

10 Schedel M, "The role of polymorphisms in ADAM33, a disintegrin and metalloprotease 33, in childhood asthma and lung function in two German populations" 7 : 91-, 2006

11 Milgrom H, "The rise of health information technology" 10 : 178-180, 2010

12 Dolhnikoff M, "The outer wall of small airways is a major site of remodeling in fatal asthma" 123 : 1090-1097, 2009

13 Garrod AE., "The incidence of alkaptonuria: a study in chemical individuality" 160 : 1616-1620, 1902

14 Hartwig C, "The histamine H4 -receptor (H4 R) regulates eosinophilic inflammation in ovalbumin-induced experimental allergic asthma in mice" 45 : 1129-1140, 2015

15 Djukanović R, "The effect of inhaled IFN-β on worsening of asthma symptoms caused by viral infections. A randomized trial" 190 : 145-154, 2014

16 Agache I, "The complex type 2 endotype in allergy and asthma: from laboratory to bedside" 15 : 29-, 2015

17 Custovic A, "The Study Team for Early Life Asthma Research (STELAR) consortium ‘Asthma e-lab’: team science bringing data, methods and investigators together" 70 : 799-801, 2015

18 Xiao Y, "TNF superfamily member 13, APRIL, inhibits allergic lung inflammation" 41 : 164-171, 2011

19 Woodruff PG, "T-helper type 2-driven inflammation defines major subphenotypes of asthma" 180 : 388-395, 2009

20 Chaudhry B, "Systematic review: impact of health information technology on quality, efficiency, and costs of medical care" 144 : 742-752, 2006

21 Goodsaid FM, "Strategic paths for biomarker qualification" 245 : 219-223, 2008

22 Blumenthal D, "Stimulating the adoption of health information technology" 360 : 1477-1479, 2009

23 Hogg JC, "Small airway obstruction in COPD: new insights based on micro-CT imaging and MRI imaging" 143 : 1436-1443, 2013

24 Vachier I, "Severe asthma is associated with a loss of LX4, an endogenous anti-inflammatory compound" 115 : 55-60, 2005

25 Agache I, "Serum IL-5 and IL-13 consistently serve as the best predictors for the blood eosinophilia phenotype in adult asthmatics" 71 : 1192-1202, 2016

26 Little FF, "Salivary inflammatory mediator profiling and correlation to clinical disease markers in asthma" 9 : e84449-, 2014

27 Parker JM, "Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma" 11 : 14-, 2011

28 Ueda T, "Role of small airways in asthma: investigation using high-resolution computed tomography" 118 : 1019-1025, 2006

29 Haworth O, "Resolvin E1 regulates interleukin 23, interferon-gamma and lipoxin A4 to promote the resolution of allergic airway inflammation" 9 : 873-879, 2008

30 Aoki H, "Resolvin E1 dampens airway inflammation and hyperresponsiveness in a murine model of asthma" 367 : 509-515, 2008

31 Gu Z, "Resolvin D1, resolvin D2 and maresin 1 activate the GSK3β anti-inflammatory axis in TLR4-engaged human monocytes" 22 : 186-195, 2016

32 Bjermer L, "Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study" 150 : 789-798, 2016

33 Grainge C, "Resistin-like molecule-β is induced following bronchoconstriction of asthmatic airways" 17 : 1094-1100, 2012

34 Wawrzyniak P, "Regulation of bronchial epithelial barrier integrity by type 2 cytokines and histone deacetylases in asthmatic patients" 139 : 93-103, 2017

35 Busse WW, "Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma" 188 : 1294-1302, 2013

36 Zietkowski Z, "RANTES in exhaled breath condensate of stable and unstable asthma patients" 102 : 1198-1202, 2008

37 European Medicines Agency, "Qualification of novel methodologies for drug development: guidance to applicants" European Medicines Agency

38 Petty JM, "Pulmonary stromal-derived factor-1 expression and effect on neutrophil recruitment during acute lung injury" 178 : 8148-8157, 2007

39 Aoki H, "Protective effect of resolvin E1 on the development of asthmatic airway inflammation" 400 : 128-133, 2010

40 Levy BD, "Protectin D1 is generated in asthma and dampens airway inflammation and hyperresponsiveness" 178 : 496-502, 2007

41 Jameson JL, "Precision medicine--personalized, problematic, and promising" 372 : 2229-2234, 2015

42 Muraro A, "Precision medicine in patients with allergic diseases: airway diseases and atopic dermatitis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology" 137 : 1347-1358, 2016

43 Wood LG, "Potentially pathogenic bacteria cultured from the sputum of stable asthmatics are associated with increased 8-isoprostane and airway neutrophilia" 44 : 146-154, 2010

44 Kelly EA, "Potential contribution of IL-7 to allergen-induced eosinophilic airway inflammation in asthma" 182 : 1404-1410, 2009

45 Jongepier H, "Polymorphisms of the ADAM33 gene are associated with accelerated lung function decline in asthma" 34 : 757-760, 2004

46 Matsusaka M, "Phenotype of asthma related with high serum periostin levels" 64 : 175-180, 2015

47 Jia G, "Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients" 130 : 647-654, 2012

48 Wagner JA, "Overview of biomarkers and surrogate endpoints in drug development" 18 : 41-46, 2002

49 Ueno T, "Osteopontin levels are elevated in patients with eosinophilic pneumonia" 15 : 1111-1121, 2010

50 Simoes DC, "Osteopontin deficiency protects against airway remodeling and hyperresponsiveness in chronic asthma" 179 : 894-902, 2009

51 Grotta MB, "Obesity increases eosinophil activity in asthmatic children and adolescents" 13 : 39-, 2013

52 Yan X, "Noninvasive analysis of the sputum transcriptome discriminates clinical phenotypes of asthma" 191 : 1116-1125, 2015

53 Gagliardo R, "Non-invasive markers of airway inflammation and remodeling in childhood asthma" 20 : 780-790, 2009

54 Agache I, "Non-eosinophilic asthma endotypes" 2 : 257-267, 2015

55 Maggon K, "New drug approvals FDA/EMA in 2010: declining R&D productivity?" Knol Publishing Guild 2011

56 Kikuchi S, "Neutrophilic inflammation and CXC chemokines in patients with refractory asthma" 149 (149): 87-93, 2009

57 Summers C, "Neutrophil kinetics in health and disease" 31 : 318-324, 2010

58 Matangkasombut P, "Natural killer T cells in the lungs of patients with asthma" 123 : 1181-1185, 2009

59 Haworth O, "NK cells are effectors for resolvin E1 in the timely resolution of allergic airway inflammation" 186 : 6129-6135, 2011

60 Brasier AR, "Molecular phenotyping of severe asthma using pattern recognition of bronchoalveolar lavage-derived cytokines" 121 : 30-37, 2008

61 Pavord ID, "Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial" 380 : 651-659, 2012

62 Nair P, "Mepolizumab for prednisone-dependent asthma with sputum eosinophilia" 360 : 985-993, 2009

63 Haldar P, "Mepolizumab and exacerbations of refractory eosinophilic asthma" 360 : 973-984, 2009

64 Peters MC, "Measures of gene expression in sputum cells can identify TH2-high and TH2-low subtypes of asthma" 133 : 388-394, 2014

65 Mukhopadhyay S, "Matrix metalloproteinase-12 is a therapeutic target for asthma in children and young adults" 126 : 70-76, 2010

66 Serhan CN, "Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions" 206 : 15-23, 2009

67 Chung KF., "Lipoxins and epoxyeicosatrienoic acids. Potential for inhibitors of soluble epoxide hydrolase in severe asthma?" 190 : 848-850, 2014

68 Corren J, "Lebrikizumab treatment in adults with asthma" 365 : 1088-1098, 2011

69 Schneeweiss S, "Learning from big health care data" 370 : 2161-2163, 2014

70 Curran CS, "Lactoferrin regulates an axis involving CD11b and CD49d integrins and the chemokines MIP-1α and MCP-1 in GM-CSF-treated human primary eosinophils" 32 : 450-461, 2012

71 Yi L, "Intelectin contributes to allergen-induced IL-25, IL-33, and TSLP expression and type 2 response in asthma and atopic dermatitis" 2017

72 Stein MM, "Innate immunity and asthma risk in amish and Hutterite farm children" 375 : 411-421, 2016

73 Månsson Kvarnhammar A, "Innate immune receptors in human airway smooth muscle cells: activation by TLR1/2, TLR3, TLR4, TLR7 and NOD1 agonists" 8 : e68701-, 2013

74 Simpson JL, "Inflammatory subtypes in asthma: assessment and identification using induced sputum" 11 : 54-61, 2006

75 Bogaert P, "Inflammatory signatures for eosinophilic vs. neutrophilic allergic pulmonary inflammation reveal critical regulatory checkpoints" 300 : L679-L690, 2011

76 Agache I, "Increased serum IL-17 is an independent risk factor for severe asthma" 104 : 1131-1137, 2010

77 Préfontaine D, "Increased expression of IL-33 in severe asthma: evidence of expression by airway smooth muscle cells" 183 : 5094-5103, 2009

78 Foley SC, "Increased expression of ADAM33 and ADAM8 with disease progression in asthma" 119 : 863-871, 2007

79 James AJ, "Increased YKL-40 and chitotriosidase in asthma and chronic obstructive pulmonary disease" 193 : 131-142, 2016

80 Fang P, "Immune modulatory effects of IL-22 on allergen-induced pulmonary inflammation" 9 : e107454-, 2014

81 Djukanovic R, "IgE-mediated asthma: new revelations and future insights" 112 : 128-129, 2016

82 Liao SC, "IL-19 induced Th2 cytokines and was up-regulated in asthma patients" 173 : 6712-6718, 2004

83 Roussel L, "IL-17 promotes p38 MAPK-dependent endothelial activation enhancing neutrophil recruitment to sites of inflammation" 184 : 4531-4537, 2010

84 Bullens DM, "IL-17 mRNA in sputum of asthmatic patients: linking T cell driven inflammation and granulocytic influx?" 7 : 135-, 2006

85 Maazi H, "ICOS: ICOS-ligand interaction is required for type 2 innate lymphoid cell function, homeostasis, and induction of airway hyperreactivity" 42 : 538-551, 2015

86 Lee YM, "High-resolution CT findings in patients with near-fatal asthma: comparison of patients with mild-to-severe asthma and normal control subjects and changes in airway abnormalities following steroid treatment" 126 : 1840-1848, 2004

87 Gibson PG, "Heterogeneity of airway inflammation in persistent asthma: evidence of neutrophilic inflammation and increased sputum interleukin-8" 119 : 1329-1336, 2001

88 Haux R., "Health information systems - past, present, future" 75 : 268-281, 2006

89 U.S. Food and Drug Administration, "Guidance for industry: pharmacogenomic data submissions" U.S. Food and Drug Administration

90 Bratke K, "Granzyme K: a novel mediator in acute airway inflammation" 63 : 1006-1011, 2008

91 Woodruff PG, "Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids" 104 : 15858-15863, 2007

92 Nicodemus-Johnson J, "Genome-wide methylation study identifies an IL-13-induced epigenetic signature in asthmatic airways" 193 : 376-385, 2016

93 Croteau-Chonka DC, "Gene expression profiling in blood provides reproducible molecular insights into asthma control" 195 : 179-188, 2017

94 Modena BD, "Gene expression in relation to exhaled nitric oxide identifies novel asthma phenotypes with unique biomolecular pathways" 190 : 1363-1372, 2014

95 Agache IO, "From phenotypes to endotypes to asthma treatment" 13 : 249-256, 2013

96 Liu G, "Fibulin-1 regulates the pathogenesis of tissue remodeling in respiratory diseases" 1 : e86380-, 2016

97 Lau JY, "Fibulin-1 is increased in asthma--a novel mediator of airway remodeling?" 5 : e13360-, 2010

98 Kanemitsu Y, "Factors contributing to an accelerated decline in pulmonary function in asthma" 63 : 181-188, 2014

99 Mutalithas K, "Expression of CCR8 is increased in asthma" 40 : 1175-1185, 2010

100 Hanania NA, "Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study" 187 : 804-811, 2013

101 Kazani S, "Exhaled breath condensate eicosanoid levels associate with asthma and its severity" 132 : 547-553, 2013

102 Muraro A, "European symposium on precision medicine in allergy and airways diseases: report of the European Union Parliament Symposium (October 14, 2015)" 71 : 583-587, 2016

103 Druilhe A, "Epithelium expression and function of retinoid receptors in asthma" 38 : 276-282, 2008

104 Ravensberg AJ, "Eotaxin-2 and eotaxin-3 expression is associated with persistent eosinophilic bronchial inflammation in patients with asthma after allergen challenge" 115 : 779-785, 2005

105 Bartemes KR, "Enhanced innate type 2 immune response in peripheral blood from patients with asthma" 134 : 671-678, 2014

106 Anderson GP, "Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease" 372 : 1107-1119, 2008

107 Agache I, "Endotypes of allergic diseases and asthma: an important step in building blocks for the future of precision medicine" 65 : 243-252, 2016

108 Agache IO, "Endotype driven treatment of asthma" 1 : 198-212, 2014

109 Ray A, "Emerging molecular phenotypes of asthma" 308 : L130-L140, 2015

110 Brightling CE, "Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial" 3 : 692-701, 2015

111 Holgate ST, "Efficacy and safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial" 37 : 1352-1359, 2011

112 Bleecker ER, "Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial" 388 : 2115-2127, 2016

113 Obase Y, "Effects of inhaled corticosteroids on metalloproteinase-8 and tissue inhibitor of metalloproteinase-1 in the airways of asthmatic children" 151 : 247-254, 2010

114 Stephan M, "Effects of dipeptidyl peptidase-4 inhibition in an animal model of experimental asthma: a matter of dose, route, and time" 1 : e00095-, 2013

115 Hicks A, "Effects of LTB4 receptor antagonism on pulmonary inflammation in rodents and non-human primates" 92 : 33-43, 2010

116 Castro M, "Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial" 181 : 116-124, 2010

117 Hoshino M, "Effect of inhaled corticosteroid on an immunoreactive thymus and activation-regulated chemokine expression in the bronchial biopsies from asthmatics" 60 : 317-322, 2005

118 Wenzel S, "Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a stud ies" 370 : 1422-1431, 2007

119 Kim SH, "Effect of active vitamin D3 on VEGF-induced ADAM33 expression and proliferation in human airway smooth muscle cells: implications for asthma treatment" 18 : 7-, 2017

120 Wenzel S, "Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial" 388 : 31-44, 2016

121 Howard R, "Distinguishing asthma phenotypes using machine learning approaches" 15 : 38-, 2015

122 Morrison D, "Digital asthma self-management interventions: a systematic review" 16 : e51-, 2014

123 Xiao C, "Defective epithelial barrier function in asthma" 128 : 549-556, 2011

124 Wilson SJ, "De Meulder B, et al. Severe asthma exists despite suppressed tissue inflammation: findings of the U-BIOPRED study" 48 : 1307-1319, 2016

125 Seys SF, "Damage-associated molecular pattern and innate cytokine release in the airways of competitive swimmers" 70 : 187-194, 2015

126 Dauletbaev N, "Could relative abundance of airway lipoxins be the clue to restore corticosteroid sensitivity in severe asthma?" 137 : 1807-1808, 2016

127 Gibson CJ, "Convergent evolution of health information management and health informatics: a perspective on the future of information professionals in health care" 6 : 163-184, 2015

128 Matui P, "Computer decision support systems for asthma: a systematic review" 24 : 14005-, 2014

129 Cabon Y, "Comparison of anti-interleukin-5 therapies in patients with severe asthma: global and indirect meta-analyses of randomized placebo-controlled trials" 47 : 129-138, 2017

130 European Medicines Agency, "Committee for Medicinal Products for Human Use. Zelboraf: summary of opinion" European Medicines Agency 2011

131 Fujita H, "Claudin-1 expression in airway smooth muscle exacerbates airway remodeling in asthmatic subjects" 127 : 1612-1621, 2011

132 Wood LG, "Characterization of innate immune signalling receptors in virus-induced acute asthma" 41 : 640-648, 2011

133 Gonem S, "Characterization of acinar airspace involvement in asthmatic patients by using inert gas washout and hyperpolarized (3)helium magnetic resonance" 137 : 417-425, 2016

134 Gunawardhana LP, "Characteristic DNA methylation profiles in peripheral blood monocytes are associated with inflammatory phenotypes of asthma" 9 : 1302-1316, 2014

135 Li Q, "Changes in expression of genes regulating airway inflammation following a high-fat mixed meal in asthmatics" 8 : E30-, 2016

136 Mutalithas K, "CRTH2 expression on T cells in asthma" 161 : 34-40, 2010

137 Gangwar RS, "CD48 on blood leukocytes and in serum of asthma patients varies with severity" 2016

138 Allakhverdi Z, "CD34+ hemopoietic progenitor cells are potent effectors of allergic inflammation" 123 : 472-478, 2009

139 Doeing DC, "Bronchial thermoplasty failure in severe persistent asthma: a case report" 50 : 799-801, 2013

140 van Staa TP, "Big health data: the need to earn public trust" 354 : i3636-, 2016

141 Williams SM, "Big data analysis on autopilot?" 6 : 22-, 2013

142 Denlinger LC, "Attenuated P2X7 pore function as a risk factor for virus-induced loss of asthma control" 179 : 265-270, 2009

143 Christenson SA, "Asthma-COPD overlap. Clinical relevance of genomic signatures of type 2 inflammation in chronic obstructive pulmonary disease" 191 : 758-766, 2015

144 Lötvall J, "Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome" 127 : 355-360, 2011

145 Cox G, "Asthma control during the year after bronchial thermoplasty" 356 : 1327-1337, 2007

146 Hoshino M, "Association of airway wall thickness with serum periostin in steroid-naive asthma" 37 : 225-230, 2016

147 Koponen P, "Association of MBL2 polymorphism with asthma after bronchiolitis in infancy" 54 : 619-622, 2012

148 Koh YI, "Association between sputum natural killer T cells and eosinophilic airway inflammation in human asthma" 153 : 239-248, 2010

149 Møller-Larsen S, "Association analysis identifies TLR7 and TLR8 as novel risk genes in asthma and related disorders" 63 : 1064-1069, 2008

150 Gao P, "Anti-inflammatory deficiencies in neutrophilic asthma: reduced galectin-3 and IL-1RA/IL-1β" 16 : 5-, 2015

151 Detoraki A, "Angiogenesis and lymphangiogenesis in bronchial asthma" 65 : 946-958, 2010

152 Hastie AT, "Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes" 125 : 1028-1036, 2010

153 de Boer WI, "Altered expression of epithelial junctional proteins in atopic asthma: possible role in inflammation" 86 : 105-112, 2008

154 Tang W, "Allergen-induced increases in interleukin-25 and interleukin-25 receptor expression in mature eosinophils from atopic asthmatics" 170 : 234-242, 2016

155 Baines KJ, "Airway β-defensin-1 protein is elevated in COPD and severe asthma" 2015 : 407271-, 2015

156 Mackay RM, "Airway surfactant protein d deficiency in adults with severe asthma" 149 : 1165-1172, 2016

157 Aysola RS, "Airway remodeling measured by multidetector CT is increased in severe asthma and correlates with pathology" 134 : 1183-1191, 2008

158 Gagliardo R, "Airway lipoxin A4/formyl peptide receptor 2-lipoxin receptor levels in pediatric patients with severe asthma" 137 : 1796-1806, 2016

159 Planagumà A, "Airway lipoxin A4 generation and lipoxin A4 receptor expression are decreased in severe asthma" 178 : 574-582, 2008

160 Samitas K, "Activin-A is overexpressed in severe asthma and is implicated in angiogenic processes" 47 : 769-782, 2016

161 Hammad H, "Activation of the D prostanoid 1 receptor suppresses asthma by modulation of lung dendritic cell function and induction of regulatory T cells" 204 : 357-367, 2007

162 Kuo CS, "A transcriptome-driven analysis of epithelial brushings and bronchial biopsies to define asthma phenotypes in U-BIOPRED" 195 : 443-455, 2017

163 Wenzel SE, "A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma" 179 : 549-558, 2009

164 Ledford D, "A randomized multicenter study evaluating Xolair persistence of response after long-term therapy" 2016

165 Chen J, "A novel peptide ADAM8 inhibitor attenuates bronchial hyperresponsiveness and Th2 cytokine mediated inflammation of murine asthmatic models" 6 : 30451-, 2016

166 Chupp GL, "A chitinase-like protein in the lung and circulation of patients with severe asthma" 357 : 2016-2027, 2007